Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 5 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus LIQUAEMIN SODIUM PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 5 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus LIQUAEMIN SODIUM PRESERVATIVE FREE.
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER vs LIQUAEMIN SODIUM PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III (ATIII) via a unique pentasaccharide sequence, inducing a conformational change that accelerates ATIII-mediated inactivation of factor Xa and thrombin (factor IIa). This prevents fibrin formation and clot propagation. It also inhibits factors IXa, XIa, and XIIa.
Heparin binds to antithrombin III, accelerating its inhibition of coagulation factors IIa (thrombin) and Xa, thereby preventing thrombus formation and extension.
Continuous IV infusion: Initial bolus of 5,000 units, then 1,000 units/hour (25,000 units/24h) adjusted based on aPTT. Typical infusion rate 10-20 units/kg/hour.
Intravenous: Initial bolus of 80 units/kg followed by continuous infusion at 18 units/kg/hour; subcutaneous: 5000 units every 8-12 hours.
None Documented
None Documented
30–150 minutes (intravenous), dose-dependent; at therapeutic doses ~60 minutes; prolonged in hepatic disease.
Terminal elimination half-life: 1-2 hours (0.5-1.5 h at therapeutic doses, dose-dependent due to saturable clearance). Context: shorter half-life in pulmonary embolism, prolonged in hepatic/renal impairment. Protamine reversal used for rapid offset.
Renal: negligible; biliary/fecal: negligible; primarily cleared by hepatic depolymerization and reticuloendothelial system uptake.
Renal: 50-70% as unchanged heparin and metabolites via saturable clearance; biliary/fecal: <5% as metabolites.
Category A/B
Category C
Anticoagulant
Anticoagulant